News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


Median Brain Cancer Survival Doubles in Vaccine Trials


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://fdanews.com/newsletter/article?issueId=11959&articleId=110418

Posted on: 09/28/2008

Median Brain Cancer Survival Doubles in Vaccine Trials

Patients with a lethal form of brain cancer who received Northwest Biotherapeutics’ DCVax-Brain in Phase I and Phase I/II clinical trials had a median survival rate that was more than double the rate for people on the standard treatment.

The testing in glioblastoma multiforme patients began in 2000 and 2003, and long-term data show that their median survival rate is 36.4 months compared with 14.6 months under the standard of care, which may include surgery, radiation and chemotherapy.

In addition, 84 percent of those who received the personalized vaccine have lived beyond the median survival point; 68 percent have lived more than two years; and 26 percent have lived more than four years. Some patients have survived as long as eight years, the company said.

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740